ASX:PNVPolynovo Stock Price, Forecast & News

A$2.49

0.00 (0.00 %)

(As of 05/12/2020)

Add

Compare

Today's Range

A$2.44

Now: A$2.49▼

A$2.58

50-Day Range

A$1.54

MA: A$2.19▼

A$2.60

52-Week Range

A$1.04

Now: A$2.49▼

A$3.29

Volume3.38 million shs

Average VolumeN/A

Market Capitalization$1.65 billion

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Polynovo Limited, a medical device company, designs, develops, and manufactures dermal regeneration solutions in Australia. The company focuses on the development and commercialization of medical devices using its NovoSorb technology in the treatment of burns, surgical wounds, and negative pressure wound therapy. It offers BTM (biodegradable temporising matrix), a wound dressing intended for treatment of full-thickness wounds and burns. In addition, Polynovo Limited licensed its NovoSorb to Smith & Nephew for orthopaedic applications. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.

Beat the Market (BTM) Rank^™

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Polynovo.

2.7 Community Rank

Outperform Votes
Polynovo has received 25 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Polynovo has received 22 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Polynovo has received 53.19% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Polynovo and other stocks. Vote “Outperform” if you believe PNV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PNV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Polynovo does not currently pay a dividend.
Dividend Growth
Polynovo does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Polynovo insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$1,839,000.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Polynovo are expected to decrease by -100.00% in the coming year, from A$0.02 to A$0.00 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Polynovo is -415.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Polynovo is -415.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Polynovo has a P/B Ratio of 67.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.14 out of 5 stars

Industry, Sector and Symbol

Stock Exchange ASX

Industry Biotechnology

Sub-IndustryN/A

SectorMedical

Current SymbolASX:PNV

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.polynovo.com.au

Phone61 3 8681 4050

Debt

Debt-to-Equity Ratio9.87

Current Ratio6.28

Quick Ratio4.56

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E Ratio117.00

P/E GrowthN/A

Sales & Book Value

Annual Sales$18.56 million

Price / Sales88.71

Cash FlowA$0.01 per share

Price / Cash Flow207.50

Book ValueA$0.04 per share

Price / Book67.30

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Employees41

Outstanding Shares661,088,000

Market Cap$1.65 billion

Next Earnings DateN/A

OptionableNot Optionable

Receive PNV News and Ratings via Email

Sign-up to receive the latest news and ratings for PNV and its competitors with MarketBeat's FREE daily newsletter.

Polynovo (ASX:PNV) Frequently Asked Questions

How has Polynovo's stock been impacted by COVID-19 (Coronavirus)?

Polynovo's stock was trading at A$1.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, PNV stock has increased by 31.1% and is now trading at A$2.49. View which stocks have been most impacted by Coronavirus.

Has Polynovo been receiving favorable news coverage?

Headlines about PNV stock have trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Polynovo earned a daily sentiment score of -4.8 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutPolynovo.

Who are some of Polynovo's key competitors?

Some companies that are related to Polynovo include MORGAN STANLEY Morgan Stanley Capital Protected Notes Based on S&P 500 (MOR), MorphoSys (MOR), Vir Biotechnology (VIR), MorphoSys (MOR), Cronos Group (CRON), BTG (BTG), Abcam (ABC), Kodiak Sciences (KOD), Genus (GNS), Mesoblast (MSB), NGM Biopharmaceuticals (NGM), Concordia International (CXR), Clinuvel Pharmaceuticals (CUV), BELLUS Health (BLU) and Trillium Therapeutics (TRIL). View all competitors.

What other stocks do shareholders of Polynovo own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Polynovo investors own include IMMUTEP LTD/S (IMMP), Rural Funds Group (RFF), iSignthis (ISX), Phoenix New Media (FENG), Eros International (EROS), Enterprise Products Partners (EPD), Canadian Solar (CSIQ), Credit Suisse Group (CS), Avita Medical (AVH) and Align Technology (ALGN).

Who are Polynovo's key executives?

Polynovo's management team includes the following people:

Mr. Paul Brennan, Chief Exec. Officer
Mr. Greg Lewis M.A.I.C.D., M.B.A., Chief Operating Officer
Mr. Jan-Marcel Gielen, CFO & Company Sec.
Dr. Tim Moore, Principal Scientist
Mr. David Smith, Manufacturing Mang.

What is Polynovo's stock symbol?

Polynovo trades on the ASX under the ticker symbol "PNV."

What is Polynovo's stock price today?

One share of PNV stock can currently be purchased for approximately A$2.49.

How big of a company is Polynovo?

Polynovo has a market capitalization of $1.65 billion and generates $18.56 million in revenue each year. Polynovo employs 41 workers across the globe.

What is Polynovo's official website?

The official website for Polynovo is www.polynovo.com.au.

How can I contact Polynovo?

The company can be reached via phone at 61 3 8681 4050.

This page was last updated on 5/26/2020 by MarketBeat.com Staff